Vitexin

Vitexin is a flavone C-glycoside found naturally in passionflower, hawthorn, and millet, where glucose is directly bonded to the carbon-8 position of the apigenin backbone. It exerts its primary biological effects by inhibiting the PI3K/AKT/mTOR signaling cascade, modulating nuclear factor-kappa B (NF-κB) activity, and activating the vitamin D receptor pathway.

Origin & History

Vitexin is a C-glycosylflavone (5,7,4'-trihydroxyflavone-8-glucoside) primarily sourced from plants such as Vitex negundo, mung bean (Vigna radiata), and hawthorn (Crataegus species). It is typically extracted using ethanol or methanol solvents from leaves, seeds, or aerial parts, followed by chromatographic purification.

Historical & Cultural Context

While vitexin itself lacks documented traditional use history, it derives from Vitex negundo, a plant used in Ayurvedic and traditional Chinese medicine for anti-inflammatory, antioxidant, and antidiabetic purposes. Lignans like vitexin have been noted in dietary contexts for potential cancer prevention.

Health Benefits

• May support colorectal health by modulating vitamin D receptor pathways and macrophage function (preliminary animal evidence)
• Shows potential anti-cancer properties through PI3K/AKT pathway inhibition in endometrial cancer models (IC50 9.89-12.35 μM in vitro)
• Demonstrates cardioprotective effects via calcineurin-NFATc3/CaMKII pathways and reduction of oxidative stress (animal studies only)
• May help regulate blood glucose levels through IRS-1/AKT insulin signaling pathways (rodent diabetes models)
• Exhibits anti-inflammatory properties through COX-1/COX-2 inhibition and NF-κB suppression (preclinical evidence)

How It Works

Vitexin inhibits the PI3K/AKT/mTOR pathway, reducing downstream phosphorylation of survival proteins that promote tumor cell proliferation, with documented IC50 values of 9.89–12.35 μM against endometrial cancer cell lines in vitro. It suppresses NF-κB nuclear translocation, thereby decreasing pro-inflammatory cytokine expression including TNF-α and IL-6. Additionally, vitexin modulates vitamin D receptor (VDR) signaling and macrophage polarization states, influencing colonic epithelial barrier integrity and immune surveillance in animal models of colorectal disease.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses on vitexin were identified in current research. All evidence is limited to preclinical in vitro and in vivo animal studies, including mouse models showing effects on colitis-associated colorectal cancer through VDR pathways and endometrial cancer suppression at 80 mg/kg over 30 days.

Clinical Summary

The current evidence base for vitexin consists almost entirely of in vitro cell studies and rodent animal models, with no completed large-scale human randomized controlled trials published as of early 2025. Animal studies have demonstrated cardioprotective effects including reduced myocardial infarct size and improved ejection fraction in ischemia-reperfusion injury models, though translation to human outcomes remains unconfirmed. In vitro anti-cancer data shows concentration-dependent apoptosis induction in endometrial, hepatic, and colorectal cancer cell lines at micromolar concentrations, but oral bioavailability challenges mean these concentrations may be difficult to achieve in human tissue. Researchers consider vitexin a promising phytochemical warranting Phase I human pharmacokinetic trials, but clinicians should not yet recommend it as a therapeutic agent for any specific condition.

Nutritional Profile

Vitexin is a pure flavone glycoside compound (apigenin-8-C-glucoside), not a food ingredient, so it has no macronutrient, vitamin, or mineral profile. Molecular weight: 432.38 g/mol. It is a C-glycosylated flavonoid, meaning the glucose moiety is directly bonded to the flavone carbon skeleton at position C-8, distinguishing it from O-glycosides. Naturally occurring concentrations in source plants: hawthorn (Crataegus spp.) leaves 0.1–1.2% dry weight; passion flower (Passiflora incarnata) aerial parts 0.5–1.5% dry weight; pearl millet up to 0.3 mg/g dry weight; bamboo leaves 0.8–2.1 mg/g dry weight. Bioavailability is notably limited due to poor aqueous solubility (~0.04 mg/mL at physiological pH) and low intestinal permeability (classified as BCS Class IV). Oral bioavailability in rodent models estimated at 3–8%. The C-glycosidic bond resists acid hydrolysis in the stomach, but colonic microbiota can partially cleave the glucose unit, generating apigenin as a secondary metabolite. Plasma half-life reported at approximately 2–4 hours in animal pharmacokinetic studies. No dietary reference intake or recommended daily allowance exists, as vitexin is not classified as an essential nutrient. Typical experimental doses in in vitro studies range from 5–100 μM; animal study doses commonly 10–50 mg/kg body weight.

Preparation & Dosage

No clinically studied human dosages exist. Preclinical studies used: in vitro 5-100 μM for various effects; in vivo 30-80 mg/kg orally or intraperitoneally in rodent models. No standardized human forms (extract percentages, powder) have been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Isovitexin, Vitamin D, Quercetin, Apigenin, Hawthorn extract

Safety & Interactions

Vitexin has demonstrated a favorable safety profile in rodent toxicology studies, with no observed adverse effect levels reported at standard experimental doses, but formal human safety data is largely absent. Due to its inhibitory effects on cytochrome P450 enzymes, particularly CYP3A4, vitexin may theoretically potentiate the effects of drugs metabolized by this pathway including statins, benzodiazepines, and certain anticoagulants, warranting caution in polypharmacy contexts. Its antiplatelet and mild hypotensive properties observed in animal models suggest additive risk when combined with anticoagulants such as warfarin or antiplatelet agents like clopidogrel. Pregnant and breastfeeding individuals should avoid supplemental vitexin due to complete absence of reproductive safety data, even though dietary exposure through passionflower or millet is considered low-risk.